People
World-leading scientists and clinicians steer Silence’s ground-breaking siRNA research programme into disease areas with high unmet medical need
Although the concept of genome editing is just starting to gain traction, it has the potential to revolutionize health care by being able to treat, and in many cases cure, previously difficult-to-treat or untreatable genetic diseases. Intellia Therapeutics is focused on implementing a full-spectrum genome editing approach.
The company will be helmed by Jes Olesen, the former president of the European Federation of Neurological Societies and chairman of the Danish Headache Center.
The trial’s goal is to test more than 700 patients infected with the coronavirus, but at this point, there have been fewer than 200 people recruited.
The U.S. Food and Drug Administration’s Office of Prescription Drug Promotion is interested in how social media affects the public’s perception of drugs.
Biopharma and life sciences companies bolster their leadership teams and board with this week’s Movers & Shakers.
The outbreak of the coronavirus, now called COVID-19, is taking some unexpected twists and turns.
The company’s efforts appear to be working, as it reported fourth-quarter results that exceeded expectations. Company shares popped 9.1% at the news.
As Sanofi continues to undergo a planned renovation announced in December, it will do so without four long-time executives.
The Life Science Women’s Conference is being held on February 19 and 20 at the Tampa Bay Convention Center in Tampa, Florida. Co-founded by Patti Rossman and Steve Fiske, the conference is an opportunity for women to accelerate their life science careers via mentoring, networking and education.
PRESS RELEASES